世界全股市ETF-Vanguard(VT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VT 世界全股市ETF-Vanguard

未开盘 05-02 16:00:00 EDT

107.64

+1.30

+1.22%

盘后108.29

+0.65+0.60%

19:59 EDT

最高107.85	最低106.48	成交量110.01万
今开107.25	昨收106.34	日振幅1.28%
总市值350.93亿	流通市值350.93亿	总股本3.26亿
成交额1.18亿	换手率0.34%	流通股本3.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"VT","market":"US","secType":"STK","nameCN":"世界全股市ETF-Vanguard","latestPrice":107.64,"timestamp":1714680000000,"preClose":106.34,"halted":0,"volume":1100134,"hourTrading":{"tag":"盘后","latestPrice":108.29,"preClose":107.64,"latestTime":"19:59 EDT","volume":849,"amount":91942.92,"timestamp":1714694342400},"delay":0,"floatShares":326024036,"shares":326024036,"eps":0,"marketStatus":"未开盘","marketStatusCode":0,"change":1.3,"latestTime":"05-02 16:00:00 EDT","open":107.25,"high":107.845,"low":106.48,"amount":117972209.40959999,"amplitude":0.012836,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"exchange":"ARCA","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714723200000},"adr":0,"adjPreClose":106.34,"adrRate":0,"sharesOutstanding":326024595,"nav":106.28,"aum":34649893956.6,"bidAskSpread":0.000101,"preHourTrading":{"tag":"盘前","latestPrice":107.69,"preClose":106.34,"latestTime":"09:26 EDT","volume":236,"amount":25478.844380000002,"timestamp":1714656412446},"postHourTrading":{"tag":"盘后","latestPrice":108.29,"preClose":107.64,"latestTime":"19:59 EDT","volume":849,"amount":91942.92,"timestamp":1714694342400},"volumeRatio":0.641881},"requestUrl":"/m/hq/s/VT/","defaultTab":"news","newsList":[{"id":"2403746070","title":"Solana跨链桥报告：Solana跨链协议和跨链Dapp全览","url":"https://stock-news.laohu8.com/highlight/detail?id=2403746070","media":"金色财经","top":-1,"share":"https://www.laohu8.com/m/news/2403746070?lang=zh_cn&edition=full","pubTime":"2024-01-16 09:34","pubTimestamp":1705368883,"startTime":"0","endTime":"0","summary":"本文目标是实现两个主要群体的意图：渴望使用消息传递协议构建跨链应用程序的开发人员，以及将资产转移到Solana以寻找下一个千倍增长模因币的用户。","market":"hk","thumbnail":"data:image/png;base64,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","type":0,"news_type":0,"thumbnails":["data:image/png;base64,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"],"rights":{"source":"jinse_stock","url":"https://www.jinse.cn/blockchain/3672871.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.jinse.cn/blockchain/3672871.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2384353860","title":"【港股通】复星医药(02196)：VT-101注射液用于治疗晚期头颈部鳞癌等实体瘤的临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2384353860","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2384353860?lang=zh_cn&edition=full","pubTime":"2023-11-17 19:00","pubTimestamp":1700218802,"startTime":"0","endTime":"0","summary":"金吾财讯 | 复星医药 公布，公司控股子公司江苏万邦医药科技有限公司及其控股子公司自主研发的VT-101注射液已分别获国家药品监督管理局和美国FDA关于同意该新药用于治疗晚期头颈部鳞癌、黑色素瘤和乳腺癌等实体瘤的临床试验批准。万邦科技拟于条件具备后分别于中国境内、美国开展该新药的I期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=2a9f8e9af34188e37523f8770e152c38","is_publish_highlight":false,"gpt_icon":0},{"id":"2384589363","title":"复星医药(02196)控股子公司自主研发的 VT-101 注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2384589363","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2384589363?lang=zh_cn&edition=full","pubTime":"2023-11-17 18:39","pubTimestamp":1700217599,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 公布，该公司控股子公司江苏万邦医药科技有限公司及其控股子公司自主研发的 VT-101 注射液已分别获国家药品监督管理局和美国 FDA关于同意该新药用于治疗晚期头颈部鳞癌、黑色素瘤和乳腺癌等实体瘤的临床试验批准。万邦科技拟于条件具备后分别于中国境内、美国开展该新药的 I 期临床试验。截至本公告日，于全球范围内已上市的溶瘤病毒产品主要包括Amgen Inc.的Imlygic。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1026076.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2384337500","title":"复星医药(600196.SH)：自主研发VT-101注射液获药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2384337500","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2384337500?lang=zh_cn&edition=full","pubTime":"2023-11-17 17:39","pubTimestamp":1700213940,"startTime":"0","endTime":"0","summary":"复星医药公告，公司控股子公司江苏万邦医药科技有限公司及其控股子公司自主研发的VT-101注射液已分别获国家药品监督管理局和美国FDA关于同意该新药用于治疗晚期头颈部鳞癌、黑色素瘤和乳腺癌等实体瘤的临床试验批准。万邦科技拟于条件具备后分别于中国境内、美国开展该新药的I期临床试验。据悉，该新药是一款具有三重肿瘤靶向调控机制、三个病毒结构基因改造、三种血清型腺病毒嵌合、三类抗癌免疫基因装载的新一代重组溶瘤腺病毒产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-11-17/doc-imzuxmnm0303869.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-11-17/doc-imzuxmnm0303869.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0082},{"period":"1month","weight":-0.0176},{"period":"3month","weight":0.0303},{"period":"6month","weight":0.1409},{"period":"1year","weight":0.171},{"period":"ytd","weight":0.0463}],"compareEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":-0.0266},{"period":"3month","weight":0.0216},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.0625}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.4375,"avgChangeRate":0.000441},{"month":2,"riseRate":0.5625,"avgChangeRate":0.00331},{"month":3,"riseRate":0.6875,"avgChangeRate":0.011764},{"month":4,"riseRate":0.75,"avgChangeRate":0.019713},{"month":5,"riseRate":0.625,"avgChangeRate":-0.002744},{"month":6,"riseRate":0.4,"avgChangeRate":-0.001838},{"month":7,"riseRate":0.75,"avgChangeRate":0.02828},{"month":8,"riseRate":0.5,"avgChangeRate":-0.0084},{"month":9,"riseRate":0.4375,"avgChangeRate":-0.015472},{"month":10,"riseRate":0.5625,"avgChangeRate":0.002443},{"month":11,"riseRate":0.6875,"avgChangeRate":0.020837},{"month":12,"riseRate":0.6875,"avgChangeRate":0.00516}],"exchange":"ARCA","name":"世界全股市ETF-Vanguard","nameEN":"Vanguard Total World Stock ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"世界全股市ETF-Vanguard(VT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供世界全股市ETF-Vanguard(VT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"世界全股市ETF-Vanguard,VT,世界全股市ETF-Vanguard股票,世界全股市ETF-Vanguard股票老虎,世界全股市ETF-Vanguard股票老虎国际,世界全股市ETF-Vanguard行情,世界全股市ETF-Vanguard股票行情,世界全股市ETF-Vanguard股价,世界全股市ETF-Vanguard股市,世界全股市ETF-Vanguard股票价格,世界全股市ETF-Vanguard股票交易,世界全股市ETF-Vanguard股票购买,世界全股市ETF-Vanguard股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"世界全股市ETF-Vanguard(VT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供世界全股市ETF-Vanguard(VT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}